Analysts’ Viewpoint
The global bioresorbable vascular scaffold market is expected to witness significant growth in the next few years due to rise in prevalence of cardiovascular diseases and rise in demand for minimally invasive procedures. Moreover, rise in healthcare expenditure along with increase in awareness about the advantages of BVS over traditional metallic stents is contributing to the global bioresorbable vascular scaffold market expansion.
Key manufacturers in the market are investing in research & development activities to develop innovative products and expand their product portfolio. The market is highly competitive, with players focusing on strategic partnerships and collaborations to expand market presence. However, high cost of BVS and lack of reimbursement policies in some regions are projected to hamper market statistics in the near future.
Bioresorbable vascular scaffold (BVS) is a medical device that can be used to treat coronary artery disease. It is a type of stent made of a biodegradable polymer material that dissolves over time, leaving behind only the natural vessel.
BVS is designed to provide temporary support to the artery, allowing it to heal and restore its natural function. It is a relatively new technology that has been developed as an alternative to traditional metal stents. BVS reduces the risk of long-term complications such as restenosis and thrombosis.
There is, however, limited long-term data on the safety and efficacy of BVS. Additionally, it is more expensive than traditional metal stents, which can be a barrier to its adoption in some healthcare systems. BVS requires a higher level of technical expertise to implant than traditional metal stents, which can limit its use in some settings.
Cardiovascular diseases (CVDs) are one of the leading causes of death globally. According to the World Health Organization, CVDs account for approximately 17.9 million deaths each year, which is about 31.0% of all global deaths. The prevalence of CVDs is increasing due to various factors such as sedentary lifestyles, unhealthy diets, and aging populations. Consequently, there is a growing demand for effective treatment options that can improve patient outcomes.
Bioresorbable vascular scaffolds have emerged as a promising alternative to traditional metallic stents in the treatment of coronary artery disease (CAD). Bioresorbable vascular scaffolds gradually dissolve over time and are absorbed by the body. This eliminates the need for long-term antiplatelet therapy and reduces the risk of late adverse events such as stent thrombosis.
As more patients seek treatment for CAD, healthcare providers would look for innovative solutions that can provide better outcomes while minimizing risks and complications associated with traditional treatments. BVS design and manufacturing processes are becoming more reliable and effective than ever before due to advancements in technology.
Minimally invasive procedures have gained popularity over traditional open surgeries due to their numerous benefits such as reduced pain, shorter hospital stays, faster recovery times, lower costs, and fewer complications. These procedures involve using small incisions or catheters instead of large surgical incisions.
Physicians increasingly prefer minimally invasive techniques when treating cardiovascular diseases such as CAD because they offer better patient outcomes. BVSs are particularly well-suited for minimally invasive procedures because they can be delivered through small catheters and do not require the use of a permanent implant.
Advancements in imaging technologies have made it easier for physicians to visualize the coronary arteries during minimally invasive procedures, making it easier to place BVSs accurately. This has further fueled interest among healthcare providers who are looking for safe and efficient alternatives to traditional stents.
In terms of product type, the sirolimus-eluting device segment is expected to dominate the global market during the forecast period., owing to its effectiveness in treating coronary artery disease.
Sirolimus-eluting devices are widely used for their ability to reduce restenosis rates and improve clinical outcomes compared to bare-metal stents. These devices release sirolimus, an immunosuppressive drug that inhibits cell proliferation and migration leading to reduced neointimal hyperplasia formation. This makes them highly effective in preventing the re-narrowing of arteries after angioplasty procedures.
Rise in prevalence of coronary artery disease (CAD) is one of the major factors driving the demand for sirolimus-eluting devices. Moreover, technological advancements have contributed significantly to the growth of the segment. For instance, MeRes100 BRS, developed by Meril Life Sciences Pvt. Ltd, is the first sirolimus-releasing bioresorbable vascular matrix to treat coronary artery disease.
Based on material type, the poly-L-lactic acid segment dominated the global market in 2022. Poly-L-lactic acid (PLLA) is a synthetic polymer that has been widely used for medical applications due to its biodegradability and biocompatibility. It has excellent mechanical properties such as high tensile strength, which makes it an ideal material for bioresorbable vascular scaffolds.
In terms of disease type, the coronary artery disease segment is projected to lead the global market in the next few years. High prevalence rate of coronary artery disease across the globe is fueling the growth of the segment.
Coronary artery disease (CAD) is a condition characterized by the narrowing or blockage of coronary arteries which supply blood to heart muscles. CAD leads to chest pain or discomfort known as angina pectoris. According to a report by World Health Organization (WHO), CAD is responsible for 17 million deaths globally each year, making it one of the leading causes of death worldwide. Hence, bioresorbable vascular scaffold market demand is expected to be high in the next few years.
According to the latest bioresorbable vascular scaffold market forecast, North America is likely to dominate the global industry during the forecast period.
Advanced healthcare facilities, high disposable income, and rise in awareness about minimally invasive procedures among patients are the significant factors fueling bioresorbable vascular scaffold market growth in the region.
Key players operating in the region are investing significantly in R&D to develop innovative products that cater to unmet clinical needs.
The bioresorbable vascular scaffold market size is anticipated to increase in Europe in the near future, owing to the strong export capabilities due to established manufacturing facilities and a skilled workforce in the region.
However, countries such as Japan and South Korea are emerging as major exporters from Asia Pacific due to their technologically advanced production processes.
Pricing plays a crucial role in determining regional dominance since it affects consumer behavior significantly. In general, prices tend to be higher in developed regions such as North America compared to developing regions such as Asia Pacific, where affordability remains a key factor influencing purchasing decisions.
As per the latest bioresorbable vascular scaffold market research, companies focus on strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the industry.
Kyoto Medical Planning Co., Ltd., BIOTRONIK Group of Companies, REVA Medical, Elixir Medical, Arterius, Meril Life Sciences Pvt. Ltd., S3V Vascular Technologies, Zorion Medical, and Medtronic (development phase) are the leading players operating in the bioresorbable vascular scaffold market.
Each of these players in the bioresorbable vascular scaffold market report has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 161.5 Mn |
|
Forecast (Value) in 2031 |
More than US$ 316.7 Mn |
|
Growth Rate (CAGR) |
7.8% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segments analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 161.5 Mn in 2022
It is projected to reach more than US$ 316.7 Mn by 2031
The industry is anticipated to grow at a CAGR of 7.8% from 2023 to 2031
Increase in prevalence of cardiovascular diseases and rise in adoption of minimally invasive procedures
The coronary artery disease type segment held largest share in 2022
North America was the more lucrative region in 2022
Kyoto Medical Planning Co., Ltd., BIOTRONIK Group of Companies, REVA Medical, Elixir Medical, Arterius, Meril Life Sciences Pvt. Ltd., S3V Vascular Technologies, Zorion Medical, and Medtronic (development phase).
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Bioresorbable Vascular Scaffold Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Development
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, 2017 - 2031
5. Key Insights
5.1. Technological Advancement
5.2. Disease Incidence and Prevalence
5.3. Regulatory Analysis
5.4. COVID-19 Impact Analysis
6. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Type, 2017 - 2031
6.3.1. Everolimus-eluting Device
6.3.2. Novolimus-eluting Device
6.3.3. Sirolimus-eluting Device
6.3.4. Others (Rapamycin, etc.)
6.4. Market Attractiveness Analysis, By Product Type
7. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease Type, 2017 - 2031
7.3.1. Coronary Artery Disease
7.3.2. Peripheral Artery Disease
7.4. Market Attractiveness Analysis, By Disease Type
8. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, by Material Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Material Type, 2017 - 2031
8.3.1. Poly-L-Lactic Acid (PLLA)
8.3.2. Tyrosine-derived Polycarbonate
8.3.3. Others (Polydioxanone, etc.)
8.4. Market Attractiveness Analysis, By Material Type
9. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017 - 2031
9.3.1. Hospital
9.3.2. Ambulatory Surgical Center
9.3.3. Cardiac Catheterization Lab
9.3.4. Others (Research Institute, etc.)
9.4. Market Attractiveness Analysis, By End-user
10. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, By Region
11. North America Bioresorbable Vascular Scaffold Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017 - 2031
11.2.1. Everolimus-eluting Device
11.2.2. Novolimus-eluting Device
11.2.3. Sirolimus-eluting Device
11.2.4. Others (Rapamycin, etc.)
11.3. Market Value Forecast, by Disease Type, 2017 - 2031
11.3.1. Coronary Artery Disease
11.3.2. Peripheral Artery Disease
11.4. Market Value Forecast, by Material Type, 2017 - 2031
11.4.1. Poly-L-Lactic Acid (PLLA)
11.4.2. Tyrosine-derived Polycarbonate
11.4.3. Others (Polydioxanone, etc.)
11.5. Market Value Forecast, by End-user, 2017 - 2031
11.5.1. Hospital
11.5.2. Ambulatory Surgical Center
11.5.3. Cardiac Catheterization Lab
11.5.4. Others (Research Institute, etc.)
11.6. Market Value Forecast, by Country, 2017 - 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Disease Type
11.7.3. By Material Type
11.7.4. By End-user
11.7.5. By Country
12. Europe Bioresorbable Vascular Scaffold Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017 - 2031
12.2.1. Everolimus-eluting Device
12.2.2. Novolimus-eluting Device
12.2.3. Sirolimus-eluting Device
12.2.4. Others (Rapamycin, etc.)
12.3. Market Value Forecast, by Disease Type, 2017 - 2031
12.3.1. Coronary Artery Disease
12.3.2. Peripheral Artery Disease
12.4. Market Value Forecast, by Material Type, 2017 - 2031
12.4.1. Poly-L-Lactic Acid (PLLA)
12.4.2. Tyrosine-derived Polycarbonate
12.4.3. Others (Polydioxanone, etc.)
12.5. Market Value Forecast, by End-user, 2017 - 2031
12.5.1. Hospital
12.5.2. Ambulatory Surgical Center
12.5.3. Cardiac Catheterization Lab
12.5.4. Others (Research Institute, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product Type
12.7.2. By Disease Type
12.7.3. By Material Type
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Bioresorbable Vascular Scaffold Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017 - 2031
13.2.1. Everolimus-eluting Device
13.2.2. Novolimus-eluting Device
13.2.3. Sirolimus-eluting Device
13.2.4. Others (Rapamycin, etc.)
13.3. Market Value Forecast, by Disease Type, 2017 - 2031
13.3.1. Coronary Artery Disease
13.3.2. Peripheral Artery Disease
13.4. Market Value Forecast, by Material Type, 2017 - 2031
13.4.1. Poly-L-Lactic Acid (PLLA)
13.4.2. Tyrosine-derived Polycarbonate
13.4.3. Others (Polydioxanone, etc.)
13.5. Market Value Forecast, by End-user, 2017 - 2031
13.5.1. Hospital
13.5.2. Ambulatory Surgical Center
13.5.3. Cardiac Catheterization Lab
13.5.4. Others (Research Institute, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product Type
13.7.2. By Disease Type
13.7.3. By Material Type
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Bioresorbable Vascular Scaffold Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2017 - 2031
14.2.1. Everolimus-eluting Device
14.2.2. Novolimus-eluting Device
14.2.3. Sirolimus-eluting Device
14.2.4. Others (Rapamycin, etc.)
14.3. Market Value Forecast, by Disease Type, 2017 - 2031
14.3.1. Coronary Artery Disease
14.3.2. Peripheral Artery Disease
14.4. Market Value Forecast, by Material Type, 2017 - 2031
14.4.1. Poly-L-Lactic Acid (PLLA)
14.4.2. Tyrosine-derived Polycarbonate
14.4.3. Others (Polydioxanone, etc.)
14.5. Market Value Forecast, by End-user, 2017 - 2031
14.5.1. Hospital
14.5.2. Ambulatory Surgical Center
14.5.3. Cardiac Catheterization Lab
14.5.4. Others (Research Institute, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product Type
14.7.2. By Disease Type
14.7.3. By Material Type
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Bioresorbable Vascular Scaffold Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2017 - 2031
15.2.1. Everolimus-eluting Device
15.2.2. Novolimus-eluting Device
15.2.3. Sirolimus-eluting Device
15.2.4. Others (Rapamycin, etc.)
15.3. Market Value Forecast, by Disease Type, 2017 - 2031
15.3.1. Coronary Artery Disease
15.3.2. Peripheral Artery Disease
15.4. Market Value Forecast, by Material Type, 2017 - 2031
15.4.1. Poly-L-Lactic Acid (PLLA)
15.4.2. Tyrosine-derived Polycarbonate
15.4.3. Others (Polydioxanone, etc.)
15.5. Market Value Forecast, by End-user, 2017 - 2031
15.5.1. Hospital
15.5.2. Ambulatory Surgical Center
15.5.3. Cardiac Catheterization Lab
15.5.4. Others (Research Institute, etc.)
15.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product Type
15.7.2. By Disease Type
15.7.3. By Material Type
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2021)
16.3. Company Profiles
16.3.1. Kyoto Medical Planning Co., Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Test Type Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. BIOTRONIK Group of Companies
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Test Type Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. REVA Medical
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Test Type Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Elixir Medical
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Test Type Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Arterius
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Test Type Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Meril Life Sciences Pvt. Ltd
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Test Type Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. S3V Vascular Technologies
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Test Type Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Zorion medical
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Test Type Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Medtronic (development phase)
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Test Type Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
List of Tables
Table 01: Global Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 02: Global Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Disease Type, 2017-2031
Table 03: Global Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Material Type, 2017-2031
Table 04: Global Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 08: North America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Disease Type, 2017-2031
Table 09: North America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Material Type, 2017-2031
Table 10: North America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 11: Europe Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 13: Europe Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Disease Type, 2017-2031
Table 14: Europe Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Material Type, 2017-2031
Table 15: Europe Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Asia Pacific Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 18: Asia Pacific Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Disease Type, 2017-2031
Table 19: Asia Pacific Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Material Type, 2017-2031
Table 20: Asia Pacific Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Latin America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 23: Latin America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Disease Type, 2017-2031
Table 24: Latin America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Material Type, 2017-2031
Table 25: Latin America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 26: Middle East & Africa Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 28: Middle East & Africa Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Disease Type, 2017-2031
Table 29: Middle East & Africa Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by Material Type, 2017-2031
Table 30: Middle East & Africa Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Bioresorbable Vascular Scaffold Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 03: Global Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 04: Global Bioresorbable Vascular Scaffold Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 05: Global Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Disease Type, 2023-2031
Figure 06: Global Bioresorbable Vascular Scaffold Market Value Share Analysis, by Material Type, 2022 and 2031
Figure 07: Global Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Material Type, 2023-2031
Figure 08: Global Bioresorbable Vascular Scaffold Market Value Share Analysis, by End-user, 2022 and 2031
Figure 09: Global Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by End-user, 2023-2031
Figure 10: Global Bioresorbable Vascular Scaffold Market Value Share Analysis, by Region, 2022 and 2031
Figure 11: Global Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Region, 2023-2031
Figure 12: North America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, 2017-2031
Figure 13: North America Bioresorbable Vascular Scaffold Market Value Share Analysis, by Country, 2022 and 2031
Figure 14: North America Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Country, 2023-2031
Figure 15: North America Bioresorbable Vascular Scaffold Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 16: North America Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 17: North America Bioresorbable Vascular Scaffold Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 18: North America Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Disease Type, 2023-2031
Figure 19: North America Bioresorbable Vascular Scaffold Market Value Share Analysis, by Material Type, 2022 and 2031
Figure 20: North America Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Material Type, 2023-2031
Figure 21: North America Bioresorbable Vascular Scaffold Market Value Share Analysis, by End-user, 2022 and 2031
Figure 22: North America Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by End-user, 2023-2031
Figure 23: Europe Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, 2017-2031
Figure 24: Europe Bioresorbable Vascular Scaffold Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 25: Europe Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 26: Europe Bioresorbable Vascular Scaffold Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 27: Europe Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 28: Europe Bioresorbable Vascular Scaffold Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 29: Europe Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Disease Type, 2023-2031
Figure 30: Europe Bioresorbable Vascular Scaffold Market Value Share Analysis, by Material Type, 2022 and 2031
Figure 31: Europe Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Material Type, 2023-2031
Figure 32: Europe Bioresorbable Vascular Scaffold Market Value Share Analysis, by End-user, 2022 and 2031
Figure 33: Europe Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by End-user, 2023-2031
Figure 34: Asia Pacific Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, 2017-2031
Figure 35: Asia Pacific Bioresorbable Vascular Scaffold Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Asia Pacific Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 37: Asia Pacific Bioresorbable Vascular Scaffold Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 38: Asia Pacific Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 39: Asia Pacific Bioresorbable Vascular Scaffold Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 40: Asia Pacific Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Disease Type, 2023-2031
Figure 41: Asia Pacific Bioresorbable Vascular Scaffold Market Value Share Analysis, by Material Type, 2022 and 2031
Figure 42: Asia Pacific Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Material Type, 2023-2031
Figure 43: Asia Pacific Bioresorbable Vascular Scaffold Market Value Share Analysis, by End-user, 2022 and 2031
Figure 44: Asia Pacific Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by End-user, 2023-2031
Figure 45: Latin America Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, 2017-2031
Figure 46: Latin America Bioresorbable Vascular Scaffold Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 47: Latin America Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 48: Latin America Bioresorbable Vascular Scaffold Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 49: Latin America Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 50: Latin America Bioresorbable Vascular Scaffold Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 51: Latin America Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Disease Type, 2023-2031
Figure 52: Latin America Bioresorbable Vascular Scaffold Market Value Share Analysis, by Material Type, 2022 and 2031
Figure 53: Latin America Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Material Type, 2023-2031
Figure 54: Latin America Bioresorbable Vascular Scaffold Market Value Share Analysis, by End-user, 2022 and 2031
Figure 55: Latin America Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by End-user, 2023-2031
Figure 56: Middle East & Africa Bioresorbable Vascular Scaffold Market Value (US$ Mn) Forecast, 2017-2031
Figure 57: Middle East & Africa Bioresorbable Vascular Scaffold Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 58: Middle East & Africa Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 59: Middle East & Africa Bioresorbable Vascular Scaffold Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 60: Middle East & Africa Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 61: Middle East & Africa Bioresorbable Vascular Scaffold Market Value Share Analysis, by Disease Type, 2022 and 2031
Figure 62: Middle East & Africa Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Disease Type, 2023-2031
Figure 63: Middle East & Africa Bioresorbable Vascular Scaffold Market Value Share Analysis, by Material Type, 2022 and 2031
Figure 64: Middle East & Africa Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by Material Type, 2023-2031
Figure 65: Middle East & Africa Bioresorbable Vascular Scaffold Market Value Share Analysis, by End-user, 2022 and 2031
Figure 66: Middle East & Africa Bioresorbable Vascular Scaffold Market Attractiveness Analysis, by End-user, 2023-2031
Figure 67: Global Bioresorbable Vascular Scaffold Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Bioresorbable Vascular Scaffold Market
*86 figures and 60 tables includes